MedTrace Logo

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-05-31

Study results available
· View outcomes & findings →

Summary

Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots.

The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after discontinuation of clopidogrel therapy is associated with an increased clotting risk. However, this theory has never been rigorously tested.

The goal of this research is to determine whether discontinuation of clopidogrel results in increased platelet function.

Conditions

  • Blood Platelets
  • Clopidogrel

Interventions

DRUG

clopidogrel + aspirin

Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.

DRUG

placebo

Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.

DRUG

Aspirin

Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.

Sponsors & Collaborators

Principal Investigators

  • Alan D. Michelson, M.D. · University of Massachusetts, Worcester

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619073 on ClinicalTrials.gov